SGLT2 Inhibitors: Glucotoxicity and Tumorigenesis Downstream the Renal Proximal Tubule?

Journal of Cellular Physiology

Volumn 231, Issue 8, 2016, Pages 1635-1637

  Bertinat, Romina ^a   Nualart, Francisco ^a   Yáñez, Alejandro J ^a,b  

^a UNIVERSITY OF CONCEPCIÓN   (Chile)

^b UNIVERSIDAD AUSTRAL DE CHILE   (Chile)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; GLUCOSE; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL; SLC5A2 PROTEIN, HUMAN; SODIUM GLUCOSE COTRANSPORTER 2;

ALBUMINURIA; ARTICLE; CARCINOGENESIS; CELL MEMBRANE; DIABETIC NEPHROPATHY; DIABETIC PATIENT; EPITHELIUM CELL; GLUCOSE ABSORPTION; GLUCOSURIA; GLUCOTOXICITY; HUMAN; KIDNEY PROXIMAL TUBULE; NEPHRON; NONHUMAN; PRIORITY JOURNAL; RENAL PROTECTION; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD; CELL TRANSFORMATION; CHEMICALLY INDUCED; DIABETES MELLITUS; DIABETIC NEPHROPATHIES; DRUG EFFECTS; GLUCOSE BLOOD LEVEL; KIDNEY TUMOR; METABOLISM; MOLECULARLY TARGETED THERAPY; PATHOLOGY; PATHOPHYSIOLOGY; RISK ASSESSMENT; RISK FACTOR;

ALBUMINURIA; ANIMALS; BLOOD GLUCOSE; CELL TRANSFORMATION, NEOPLASTIC; DIABETES MELLITUS; DIABETIC NEPHROPATHIES; GLYCOSURIA; HUMANS; HYPOGLYCEMIC AGENTS; KIDNEY NEOPLASMS; KIDNEY TUBULES, PROXIMAL; MOLECULAR TARGETED THERAPY; RISK ASSESSMENT; RISK FACTORS; SODIUM-GLUCOSE TRANSPORTER 2;

EID: 84952838207     PISSN: 00219541     EISSN: 10974652     Source Type: Journal    
DOI: 10.1002/jcp.25286     Document Type: Article

References (38)

1. Cherney DZ, Perkins BA, Soleymanlou N, Maione M, Lai V, Lee A, Fagan NM, Woerle HJ, Johansen OE, Broedl UC, von Eynatten M. 2014. Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation 129:587-597.
2. Dizin E, Hasler U, Nlandu-Khodo S, Fila M, Roth I, Ernandez T, Doucet A, Martin PY, Feraille E, de Seigneux S. 2013. Albuminuria induces a proinflammatory and profibrotic response in cortical collecting ducts via the 24p3 receptor. Am J Physiol Renal Physiol 305:F1053-F1063.
3. Dombrowski F, Klotz L, Bannasch P, Evert M. 2007. Renal carcinogenesis in models of diabetes in rats: Metabolic changes are closely related to neoplastic development. Diabetologia 50:2580-2590.
4. Erkan E. 2013. Proteinuria: It is time to look beyond the proximal tubule. Am J Physiol Renal Physiol 305:F1107-F1108.
5. Gallo LA, Wright EM, Vallon V. 2015. Probing SGLT2 as a therapeutic target for diabetes: Basic physiology and consequences. Diab Vasc Dis Res 12:78-89.
6. Gangadharan Komala M, Gross S, Mudaliar H, Huang C, Pegg K, Mather A, Shen S, Pollock CA, Panchapakesan U. 2014. Inhibition of kidney proximal tubular glucose reabsorption does not prevent against diabetic nephropathy in type 1 diabetic eNOS knockout mice. PLoS ONE 9:e108994.
7. Gatica R, Bertinat R, Silva P, Kairath P, Slebe F, Pardo F, Ramírez MJ, Slebe JC, Campistol JM, Nualart F, Caelles C, Yáñez AJ. 2015. Over-expression of muscle glycogen synthase in human diabetic nephropathy. Histochem Cell Biol 143:313-324.
8. Gorriz JL, Nieto J, Navarro-González JF, Molina P, Martínez-Castelao A, Pallardó LM. 2015. Nephroprotection by hypoglycemic agents: Do we have supporting data? J Clin Med 4:1866-1889.
9. Gosmanov AR, Wall BM, Gosmanova EO. 2014. Diagnosis and treatment of diabetic kidney disease. Am J Med Sci 347:406-413.
10. Hills CE, Bland R, Squires PE. 2012. Functional expression of TRPV4 channels in human collecting duct cells: Implications for secondary hypertension in diabetic nephropathy. Exp Diabetes Res 2012:936518.
11. Kang J, Dai XS, Yu TB, Wen B, Yang ZW. 2005. Glycogen accumulation in renal tubules, a key morphological change in the diabetic rat kidney. Acta Diabetol 42:110-116.
12. Kim GW, Chung SH. 2014. Clinical implication of SGLT2 inhibitors in type 2 diabetes. Arch Pharm Res 37:957-966.
13. Lau X, Zhang Y, Kelly DJ, Stapleton DI. 2013. Attenuation of Armanni-Ebstein lesions in a rat model of diabetes by a new anti-fibrotic, anti-inflammatory agent, FT011. Diabetologia 56:579-675.
14. Lin HW, Tseng CH. 2014. A review on the relationship between SGLT2 inhibitors and cancer. Int J Endocrinol 2014:719578.
15. Lin B, Koibuchi N, Hasegawa Y, Sueta D, Toyama K, Uekawa K, Ma M, Nakagawa T, Kusaka H, Kim-Mitsuyama S. 2014. Glycemic control with empagliflozin, a novel selective SGLT2 inhibitor, ameliorates cardiovascular injury and cognitive dysfunction in obese and type 2 diabetic mice. Cardiovasc Diabetol 13:148.
16. Linden KC, DeHaan CL, Zhang Y, Glowacka S, Cox AJ, Kelly DJ, Rogers S. 2006. Renal expression and localization of the facilitative glucose transporters GLUT1 and GLUT12 in animal models of hypertension and diabetic nephropathy. Am J Physiol Renal Physiol 290:F205-F213.
17. Liu X, Hemminki K, Försti A, Sundquist K, Sundquist J, Ji J. 2015. Cancer risk in patients with type 2 diabetes mellitus and their relatives. Int J Cancer 137:903-910.
18. Ly JP, Onay T, Sison K, Sivaskandarajah G, Sabbisetti V, Li L, Bonventre JV, Flenniken A, Paragas N, Barasch JM, Adamson SL, Osborne L, Rossant J, Schnermann J, Quaggin SE. 2011. The sweet pee model for Sglt2 mutation. J Am Soc Nephrol 22:113-123.
19. Ojima A, Onay T, Sison K, Sivaskandarajah G, Sabbisetti V, Li L, Bonventre JV, Flenniken A, Paragas N, Barasch JM, Adamson SL, Osborne L, Rossant J, Schnermann J, Quaggin SE. 2015. Empagliflozin, an inhibitor of sodium-glucose cotransporter 2 exerts anti-inflammatory and antifibrotic effects on experimental diabetic nephropathy partly by suppressing AGEs-receptor axis. Horm Metab Res 47:686-692.
20. Panchapakesan U, Pegg K, Gross S, Komala MG, Mudaliar H, Forbes J, Pollock C, Mather A. 2013. Effects of SGLT2 inhibition in human kidney proximal tubular cells-renoprotection in diabetic nephropathy? PLoS ONE 8:e54442.
21. Pujol-Gimenez J, de Heredia FP, Idoate MA, Airley R, Lostao MP, Evans AR. 2015a. Could GLUT12 be a potential therapeutic target in cancer treatment? A preliminary report. J Cancer 6:139-143.
22. Pujol-Gimenez J, Pérez A, Reyes AM, Loo DD, Lostao MP. 2015b. Functional characterization of the human facilitative glucose transporter 12 (GLUT12) by electrophysiological methods. Am J Physiol Cell Physiol 308:C1008-C1022.
23. Ribback S, Cigliano A, Kroeger N, Pilo MG, Terracciano L, Burchardt M, Bannasch P, Calvisi DF, Dombrowski F. 2015. PI3K/AKT/mTOR pathway plays a major pathogenetic role in glycogen accumulation and tumor development in renal distal tubules of rats and men. Oncotarget 6:13036-13048.
24. Rieg T, Masuda T, Gerasimova M, Mayoux E, Platt K, Powell DR, Thomson SC, Koepsell H, Vallon V. 2014. Increase in SGLT1-mediated transport explains renal glucose reabsorption during genetic and pharmacological SGLT2 inhibition in euglycemia. Am J Physiol Renal Physiol 306:F188-F193.
25. Ritchie S, Waugh D. 1957. The pathology of Armanni-Ebstein diabetic nephropathy. Am J Pathol 33:1035-1057.
26. Ros S, Schulze A. 2012. Linking glycogen and senescence in cancer cells. Cell Metab 16:687-688.
27. Santer R, Calado J. 2010. Familial renal glucosuria and SGL T2: From a mendelian trait to a therapeutic target. Clin J Am Soc Nephrol 5:133-141.
28. Singh DK, Winocour P, Farrington K. 2008. Mechanisms of disease: The hypoxic tubular hypothesis of diabetic nephropathy. Nat Clin Pract Nephrol 4:216-226.
29. Stuart CA, Howell ME, Zhang Y, Yin D. 2009. Insulin-stimulated translocation of glucose transporter (GLUT) 12 parallels that of GLUT4 in normal muscle. J Clin Endocrinol Metab 94:3535-3542.
30. Tahara A, Kurosaki E, Yokono M, Yamajuku D, Kihara R, Hayashizaki Y, Takasu T, Imamura M, Qun L, Tomiyama H, Kobayashi Y, Noda A, Sasamata M, Shibasaki M. 2012. Pharmacological profile of ipragliflozin (ASP1941), a novel selective SGLT2 inhibitor, in vitro and in vivo. Naunyn Schmiedebergs Arch Pharmacol 385:423-436.
31. Vallon V, Rose M, Gerasimova M, Satriano J, Platt KA, Koepsell H, Cunard R, Sharma K, Thomson SC, Rieg T. 2013. Knockout of Na-glucose transporter SGLT2 attenuates hyperglycemia and glomerular hyperfiltration but not kidney growth or injury in diabetes mellitus. Am J Physiol Renal Physiol 304:F156-F167.
32. Vallon V, Gerasimova M, Rose MA, Masuda T, Satriano J, Mayoux E, Koepsell H, Thomson SC, Rieg T. 2014. SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice. Am J Physiol Renal Physiol 306:F194-F204.
33. Vallon V. 2011. The proximal tubule in the pathophysiology of the diabetic kidney. Am J Physiol Regul Integr Comp Physiol 300:R1009-R1022.
34. Vogetseder A, Picard N, Gaspert A, Walch M, Kaissling B, Le Hir M. 2008. Proliferation capacity of the renal proximal tubule involves the bulk of differentiated epithelial cells. Am J Physiol Cell Physiol 294:C22-C28.
35. Washio M, Mori M, Khan M, Sakauchi F, Watanabe Y, Ozasa K, Hayashi K, Miki T, Nakao M, Mikami K, Ito Y, Kubo T, Wakai K, Tamakoshi A; JACC Study Group. 2007. Diabetes mellitus and kidney cancer risk: The results of Japan Collaborative Cohort Study for evaluation of cancer risk (JACC Study). Int J Urol 14:393-397.
36. Wilson-O'Brien AL, Dehaan CL, Rogers S. 2008. Mitogen-stimulated and rapamycin-sensitive glucose transporter 12 targeting and functional glucose transport in renal epithelial cells. Endocrinology 149:917-924.
37. Yanez AJ, Ludwig HC, Bertinat R, Spichiger C, Gatica R, Berlien G, Leon O, Brito M, Concha II, Slebe JC. 2005. Different involvement for aldolase isoenzymes in kidney glucose metabolism: Aldolase B but not aldolase A colocalizes and forms a complex with FBPase. J Cell Physiol 202:743-753.
38. Zanoli L, Granata A, Lentini P, Rastelli S, Fatuzzo P, Rapisarda F, Castellino P. 2015. Sodium-glucose linked transporter-2 inhibitors in chronic kidney disease. Sci World J 2015:317507.